Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Immunotherapy

CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives

Leukemia volume 33, pages 2767–2778 (2019)Cite this article

Subjects

Abstract

The approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hematologic malignancies. These anti-CD19 chimeric antigen receptor-T cells (CAR) proved to be highly effective in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and specific histologic subtypes of B-cell non-Hodgkin lymphomas. This expert review aims to summarize the current available research evidence in this field, with a special focus on the different challenges faced by treating physicians, and we also provide future perspectives.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Buechner J, Kersten MJ, Fuchs M, Salmon F, Jäger U. Chimeric antigen receptor-T cell therapy: practical considerations for implementation in. Eur HemaSphere. 2018;2:e18.

    Google Scholar 

  2. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–5.

    CAS  PubMed  Google Scholar 

  3. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372–85.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer. 2013;13:525–41.

    CAS  PubMed  Google Scholar 

  5. Park JH, Brentjens RJ. Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med. 2010;9:277–88.

    PubMed  PubMed Central  Google Scholar 

  6. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995;18:385–97.

    CAS  PubMed  Google Scholar 

  7. Sommermeyer D, Hill T, Shamah SM, Salter AI, Chen Y, Mohler KM, et al. Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia. 2017;31:2191–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Sadelain M. CAR therapy: the CD19 paradigm. J Clin Investig. 2015;125:3392–400.

    PubMed  PubMed Central  Google Scholar 

  9. Castella M, Boronat A, Martin-Ibanez R, Rodriguez V, Sune G, Caballero M, et al. Development of a novel anti-CD19 chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions. Mol Ther Methods Clin Dev. 2019;12:134–44.

    CAS  PubMed  Google Scholar 

  10. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944–50.

    CAS  PubMed  Google Scholar 

  11. Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21:1907–14.

    CAS  PubMed  Google Scholar 

  12. Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013;14:e205–217.

    PubMed  Google Scholar 

  13. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517–28.

    CAS  PubMed  Google Scholar 

  14. Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. New Engl J Med. 2018;378:449–59.

    CAS  PubMed  Google Scholar 

  15. Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler HJ, Schlosser HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6:56.

    PubMed  PubMed Central  Google Scholar 

  17. Frey NV, Porter DL. CAR T-cells merge into the fast lane of cancer care. Am J Hematol. 2016;91:146–50.

    CAS  PubMed  Google Scholar 

  18. Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13:370–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133:1652–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Novartis Pharmaceuticals Corporation. KYMRIAH [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017.

  21. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New Engl J Med. 2018;378:439–48.

    CAS  PubMed  Google Scholar 

  22. Wierda WG, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, et al. Updated phase 1 results of Zuma-3: Kte-C19, an Anti-CD19 chimeric antigen receptor T cell therapy, in adult patients with relapsed/refractory acute lymphoblastic leukemia. Blood. 2018;132:897.

    Google Scholar 

  23. Lee DW, Wayne AS, Huynh V, Handgretinger R, Pieters R, Michele G, et al. 1008PDZUMA-4 preliminary results: phase 1 study of KTE-C19 chimeric antigen receptor T cell therapy in pediatric and adolescent patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL). Ann Oncol. 2017;28.

  24. Maffini E, Saraceni F, Lanzavolume F. Treatment of adult patients with relapsed/refractory B-Cell philadelphia-negative acute lymphoblastic leukemia. Clin Hematol Int. 2019;1:85–93.

  25. Jacoby E. Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies. Clin Hematol Int. 2019;1:79–84.

  26. Children’ Oncology Group. Study of efficacy and safety of tisagenlecleucel in HR B-ALL EOC MRD positive patients (CASSIOPEIA). ClinicalTrials.gov Identifier: NCT03876769.

  27. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, et al. A comparison of one year outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in patients with refractory, aggressive non-hodgkinlymphoma (NHL). Blood. 2017;130:579.

    Google Scholar 

  29. Lulla PD, Hill LC, Ramos CA, Heslop HE. The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2018;16:375–86.

    PubMed  PubMed Central  Google Scholar 

  30. YESCARTA [package insert]. Santa Monica, CA: Kite Pharma, Inc; 2017.

  31. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New Engl J Med. 2017;377:2531–44.

    CAS  PubMed  Google Scholar 

  32. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31–42.

    CAS  PubMed  Google Scholar 

  33. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New Engl J Med. 2019;380:45–56.

    CAS  PubMed  Google Scholar 

  34. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric antigen receptor T cells in refractory B-Cell Lymphomas. New Engl J Med. 2017;377:2545–54.

    CAS  PubMed  Google Scholar 

  35. Abramson JS, Gordon LI, Palomba ML, Lunning MA, Arnason JE, Forero-Torres A, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol. 2018;36:7505–7505.

    Google Scholar 

  36. Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019;133:1876–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Neelapu SS. CAR-T efficacy: is conditioning the key? Blood. 2019;133:1799–800.

    CAS  PubMed  Google Scholar 

  38. Sauter C, Riviere I, Senechal B, Ni A, Bernal Y, Wang X, et al. A phase I trial of 19-28Z car-T cells post-high dose therapy and autologous transplantation (HDT-ASCT) for relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (B-NHL). Hematological Oncol. 2017;35:138–9.

    Google Scholar 

  39. Oluwole OO, Bishop MR, Gisselbrecht C, Gordon LI, Kersten MJ, Maloney DG, et al. ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). J Clin Oncol. 2018;36:TPS7585–TPS7585.

    Google Scholar 

  40. Abramson JS, McGree B, Noyes S, Plummer S, Wong C, Chen Y-B, et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. New Engl J Med. 2017;377:783–4.

    PubMed  Google Scholar 

  41. Chong EA, Svoboda J, Dwivedy Nasta S, Landsburg DJ, Winchell N, Napier E, et al. Sequential Anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-hodgkin lymphomas. Blood. 2018;132:4198.

    Google Scholar 

  42. Hirayama AV, Gauthier J, Hay KA, Sheih A, Cherian S, Chen X, et al. Efficacy and toxicity of JCAR014 in combination with durvalumab for the treatment of patients with relapsed/refractory aggressive B-cell non-hodgkin lymphoma. Blood. 2018;132:1680.

    Google Scholar 

  43. Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, et al. Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. Blood. 2018;132:1022–6.

    CAS  PubMed  Google Scholar 

  44. Ramos CA, Bilgi M, Gerken CP, Dakhova O, Mei Z, Grilley BJ, et al. CD30-chimeric antigen receptor (CAR) T cells for therapy of hodgkin lymphoma (HL). Blood. 2018;132:680.

    Google Scholar 

  45. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New Engl J Med. 2013;369:32–42.

    CAS  PubMed  Google Scholar 

  46. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. New Engl J Med. 2014;370:997–1007.

    CAS  PubMed  Google Scholar 

  47. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8.

    CAS  PubMed  Google Scholar 

  48. Flinn IW, Hillmen P, Montillo M, Nagy Z, Illes A, Etienne G, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132:2446–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. New Engl J Med. 2014;370:1101–10.

    CAS  PubMed  Google Scholar 

  50. D’Souza A, Fretham C. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR Summary Slides. 2018. https://www.cibmtr.org.

  51. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303ra139.

    PubMed  PubMed Central  Google Scholar 

  52. Geyer MB, Riviere I, Senechal B, Wang X, Wang Y, Purdon TJ, et al. Autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy. Mol Ther. 2018;26:1896–905.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol. 2017;35:3010–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127:1117–27.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Gill SI, Vides V, Frey NV, Metzger S, Brien M, Hexner E, et al. Prospective clinical trial of anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate. Blood. 2018;132:298.

    Google Scholar 

  56. Gauthier J, Hirayama AV, Hay KA, Li D, Lymp J, Sheih A, et al. Comparison of efficacy and toxicity of CD19-specific chimeric antigen receptor T-cells alone or in combination with ibrutinib for relapsed and/or refractory CLL. Blood. 2018;132:299.

    Google Scholar 

  57. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Azoulay E, Shimabukuro-Vornhagen A, Darmon M, von Bergwelt-Baildon M. Critical care management of chimeric antigen receptor T cell-related toxicity. Be aware and prepared. Am J respiratory Crit care Med. 2019;200:20–3.

    Google Scholar 

  59. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Teachey DT, Bishop MR, Maloney DG, Grupp SA. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit ‘ALL’. Nat Rev Clin Oncol. 2018;15:218.

    PubMed  Google Scholar 

  61. Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404–19.

    CAS  PubMed  PubMed Central  Google Scholar 

  62. Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8:958–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Sanchez-Escamilla M, Yanez San Segundo L, Urbano-Ispizua A, Perales MA. CAR T cells: the future is already present. Med Clin. 2019;152:281–6.

    Google Scholar 

  64. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–38.

    CAS  PubMed  Google Scholar 

  65. Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, et al. Clinical utilization of chimeric antigen receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for blood and marrow transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone marrow Transpl. 2019. [Epub ahead of print].

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI insight. 2019;4:127684.

    PubMed  Google Scholar 

  67. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in relapsed or refractory multiple myeloma. New Engl J Med. 2019;380:1726–37.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France

    Mohamad Mohty & Florent Malard

  2. Clinical Research Division, Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Jordan Gautier

  3. Oncology Center, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

    Mahmoud Aljurf

  4. Department of Internal Medicine/ American University of Beirut, Beirut, Lebanon

    Ali Bazarbachi

  5. Institut Paoli-Calmettes, Inserm CBT-1409 & Aix-Marseille Université, Marseille, France

    Christian Chabannon

  6. Blood and Marrow Transplantation Program, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA

    Mohamed A. Kharfan-Dabaja

  7. Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN, USA

    Bipin N. Savani

  8. Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Institute of Hematology, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 310058, China

    He Huang

  9. Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA

    Saad Kenderian

  10. The Chaim Sheba Medical Center, Tel-Hashomer, Affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    Arnon Nagler

  11. Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Miguel-Angel Perales

  12. Department of Medicine, Weill Cornell Medical College, New York, NY, USA

    Miguel-Angel Perales

Authors
  1. Mohamad Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jordan Gautier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Florent Malard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mahmoud Aljurf
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ali Bazarbachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christian Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mohamed A. Kharfan-Dabaja
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bipin N. Savani
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. He Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Saad Kenderian
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Arnon Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Miguel-Angel Perales
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed substantially to the conception, writing, critical review and final approval of the manuscript.

Corresponding author

Correspondence to Mohamad Mohty.

Ethics declarations

Conflict of interest

MAP reports honoraria from Abbvie, Bellicum, Bristol-Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, and Takeda. He serves on DSMBs for Servier and Medigene, and the scientific advisory boards of MolMed and NexImmune. He has received research support for clinical trials from Incyte, Kite (Gilead) and Miltenyi. Christian Chabanon reports honoraria from Kite/Gilead and Novartis. The remaining authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohty, M., Gautier, J., Malard, F. et al. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia 33, 2767–2778 (2019). https://doi.org/10.1038/s41375-019-0615-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-019-0615-5

This article is cited by

Search

Advanced search

Quick links